During disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs. We review evidence of the ten most recent reports on remdesivir. We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention during the COVID-19 pandemic. (C) 2020 The Author(s). Published by Elsevier Ltd.
机构:
Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USAUniv North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA
Edwards, Jessie K.
Cole, Stephen R.
论文数: 0引用数: 0
h-index: 0
机构:
Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USAUniv North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA
Cole, Stephen R.
Adimora, Adaora A.
论文数: 0引用数: 0
h-index: 0
机构:
Univ North Carolina Chapel Hill, Sch Med, Chapel Hill, NC 27599 USAUniv North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA
机构:
Univ Toronto, Dept Med, Toronto, ON, Canada
Univ Toronto, Div Clin Pharmacol & Toxicol, Toronto, ON, Canada
Univ Hlth Network, Div Gen Internal Med & Geriatr, Toronto, ON, CanadaUniv Toronto, Dept Med, Toronto, ON, Canada
Wu, Peter E.
Morris, Andrew M.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Toronto, Dept Med, Toronto, ON, Canada
Univ Toronto, Div Infect Dis, Toronto, ON, Canada
Sinai Hlth, Div Infect Dis, Toronto, ON, CanadaUniv Toronto, Dept Med, Toronto, ON, Canada